Estrella Immunopharma, Inc.
ESLA
$0.7936
-$0.0428-5.12%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 30.74% | 355.93% | 406.72% | 445.56% | 400.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.71% | -34.23% | -35.58% | 21.49% | 138.54% |
| Operating Income | 12.71% | 34.23% | 35.58% | -21.49% | -138.54% |
| Income Before Tax | 12.71% | 34.23% | 35.58% | -21.49% | -138.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.69% | 34.21% | 35.58% | -21.49% | -138.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.69% | 34.21% | 35.58% | -21.49% | -138.54% |
| EBIT | 12.71% | 34.23% | 35.58% | -21.49% | -138.54% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 99.21% | 96.96% | 89.55% | 72.73% | 16.57% |
| Normalized Basic EPS | 99.21% | 96.96% | 90.11% | 74.40% | 23.74% |
| EPS Diluted | 99.21% | 96.96% | 89.55% | 72.73% | 16.57% |
| Normalized Diluted EPS | 99.21% | 96.96% | 90.11% | 74.40% | 23.74% |
| Average Basic Shares Outstanding | 6,564.85% | 9,049.14% | 9,346.12% | 8,571.83% | 727.85% |
| Average Diluted Shares Outstanding | 6,564.85% | 9,049.14% | 9,346.12% | 8,571.83% | 727.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |